Sentry Investment Management LLC Invests $71,000 in Revvity, Inc. (NYSE:RVTY)

Sentry Investment Management LLC bought a new stake in Revvity, Inc. (NYSE:RVTY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 650 shares of the company’s stock, valued at approximately $71,000.

Several other hedge funds have also recently added to or reduced their stakes in RVTY. Mackenzie Financial Corp bought a new stake in shares of Revvity in the 4th quarter valued at about $1,518,000. Vontobel Holding Ltd. bought a new stake in Revvity in the fourth quarter valued at approximately $429,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in Revvity in the fourth quarter worth $33,568,000. Mn Services Vermogensbeheer B.V. bought a new position in shares of Revvity during the fourth quarter worth $6,340,000. Finally, Louisiana State Employees Retirement System acquired a new position in shares of Revvity in the 4th quarter valued at $820,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Trading Down 1.2 %

Revvity stock opened at $99.33 on Friday. The company has a market cap of $12.27 billion, a price-to-earnings ratio of 18.06, a P/E/G ratio of 2.61 and a beta of 1.09. The firm has a 50-day moving average of $104.83 and a 200-day moving average of $101.69. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.07 and a quick ratio of 1.77. Revvity, Inc. has a one year low of $79.50 and a one year high of $135.88.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Thursday, February 1st. The company reported $1.25 EPS for the quarter, beating the consensus estimate of $1.15 by $0.10. The firm had revenue of $695.90 million during the quarter. Revvity had a return on equity of 7.41% and a net margin of 25.20%. On average, equities analysts expect that Revvity, Inc. will post 4.65 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.28%. Revvity’s payout ratio is 5.09%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on RVTY. Raymond James lifted their target price on Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Stifel Nicolaus boosted their price objective on Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research report on Friday, February 2nd. Barclays raised their target price on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. UBS Group lowered shares of Revvity from a “buy” rating to a “neutral” rating and lifted their price target for the company from $105.00 to $125.00 in a research note on Tuesday, January 16th. Finally, KeyCorp raised their price objective on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $118.91.

Insiders Place Their Bets

In other news, insider Prahlad R. Singh sold 21,217 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the transaction, the insider now directly owns 92,801 shares in the company, valued at approximately $9,677,288.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.60% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.